Literature DB >> 12218055

Regulation of integrin function by CD47 ligands. Differential effects on alpha vbeta 3 and alpha 4beta1 integrin-mediated adhesion.

Heba O Barazi1, Zhuqing Li, Jo Anne Cashel, Henry C Krutzsch, Douglas S Annis, Deane F Mosher, David D Roberts.   

Abstract

We examined the regulation of alpha4beta1 integrin function in melanoma cells and T cells by ligands of CD47. A CD47 antibody (B6H12) that inhibited alphavbeta3-mediated adhesion of melanoma cells induced by CD47-binding peptides from thrombospondin-1 directly stimulated alpha4beta1-mediated adhesion of the same cells to vascular cell adhesion molecule-1 and N-terminal regions of thrombospondin-1 or thrombospondin-2. B6H12 also stimulated alpha4beta1- as well as alpha2beta1- and alpha5beta1-mediated adhesion of CD47-expressing T cells but not of CD47-deficient T cells. alpha4beta1 and CD47 co-purified as a detergent-stable complex on a CD47 antibody affinity column. CD47-binding peptides based on C-terminal sequences of thrombospondin-1 also specifically enhanced adhesion of melanoma cells and T cells to alpha4beta1 ligands. Unexpectedly, activation of alpha4beta1 function by the thrombospondin-1 CD47-binding peptides also occurred in CD47-deficient T cells. CD47-independent activation of alpha4beta1 required the Val-Val-Met (VVM) motif of the peptides and was sensitive to inhibition by pertussis toxin. These results indicate that activation of alpha4beta1 by the CD47 antibody B6H12 and by VVM peptides occurs by different mechanisms. The antibody directly activates a CD47-alpha4beta1 complex, whereas VVM peptides may target an unidentified Gi-linked receptor that regulates alpha4beta1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218055     DOI: 10.1074/jbc.M206849200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47.

Authors:  Sukhbir Kaur; Gema Martin-Manso; Michael L Pendrak; Susan H Garfield; Jeff S Isenberg; David D Roberts
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

Review 2.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest.

Authors:  E Sick; A Jeanne; C Schneider; S Dedieu; K Takeda; L Martiny
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

3.  Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Authors:  David D Roberts; Sukhbir Kaur; Jeffrey S Isenberg
Journal:  Antioxid Redox Signal       Date:  2017-09-08       Impact factor: 8.401

Review 4.  CD47: a new target in cardiovascular therapy.

Authors:  Jeff S Isenberg; David D Roberts; William A Frazier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-10       Impact factor: 8.311

5.  A function-blocking CD47 antibody modulates extracellular vesicle-mediated intercellular signaling between breast carcinoma cells and endothelial cells.

Authors:  Sukhbir Kaur; Abdel G Elkahloun; Satya P Singh; Anush Arakelyan; David D Roberts
Journal:  J Cell Commun Signal       Date:  2017-11-29       Impact factor: 5.782

6.  Endothelial CD47 promotes vascular endothelial-cadherin tyrosine phosphorylation and participates in T cell recruitment at sites of inflammation in vivo.

Authors:  Veronica Azcutia; Michael Stefanidakis; Naotake Tsuboi; Tanya Mayadas; Kevin J Croce; Daiju Fukuda; Masanori Aikawa; Gail Newton; Francis W Luscinskas
Journal:  J Immunol       Date:  2012-07-18       Impact factor: 5.422

7.  Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1.

Authors:  Sukhbir Kaur; Svetlana A Kuznetsova; Michael L Pendrak; John M Sipes; Martin J Romeo; Zhuqing Li; Lijuan Zhang; David D Roberts
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

Review 8.  CD47: role in the immune system and application to cancer therapy.

Authors:  Seyed Mohammad Gheibi Hayat; Vanessa Bianconi; Matteo Pirro; Mahmoud R Jaafari; Mahdi Hatamipour; Amirhossein Sahebkar
Journal:  Cell Oncol (Dordr)       Date:  2019-08-14       Impact factor: 6.730

9.  Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation.

Authors:  Thomas W Miller; Sukhbir Kaur; Kelly Ivins-O'Keefe; David D Roberts
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

10.  Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling.

Authors:  Jeff S Isenberg; Martin J Romeo; Christine Yu; Christine K Yu; Khauh Nghiem; Jude Monsale; Margaret E Rick; David A Wink; William A Frazier; David D Roberts
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.